Surrey Heartlands

Joint Formulary & PAD

Oxybutynin - Hyperhidrosis

You are here : Home > Formulary Search > Oxybutynin - Hyperhidrosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Capsules
  • Capsules (slow release)
  • Tablets
  • Tablets (slow release)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important
On recommendation from specialist team. Modified release may be used for patients with intolerable side effects to IR formulation
 

Status 2

Non Formulary
Formulations :
  • Elixir
  • Liquid
  • Oral solution
  • Oral suspension
  • Patches
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Oxybutynin
Indication :
Hyperhidrosis
Group Name :
Keywords :
antimuscarinics
Brand Names Include :
Ditropan, Lyrinel, Kentera
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Oxybutynin is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Hyperhidrosis.

  • No records returned.

Committee Recommendations (1)

04 May 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agree the traffic light status of the antimuscarinic preparations as follows:

Note that advice provided in CKS should be followed prior to initiation of the treatments below:

Oxybutynin (off label for hyperhidrosis)
BLUE on recommendation by the specialist team 

  • Immediate release (IR) preferred choice antimuscarinic treatment option 
  • Modified release (MR) preparation may be used for patients with intolerable side effects to IR preparation.

All other oxybutynin formulations (Liquid and patches) for hyperhidrosis

  • Non-formulary

Propantheline (licensed for hyperhidrosis)
BLUE on recommendation from the specialist team 

  • Offered after oxybutynin if intolerable side effects or inefficacy to that treatment

Glycopyrronium oral (off label for hyperhidrosis)
RED traffic light status

  • Treatment choice after oxybutynin and propantheline if they have not been tolerated or have not been effective
  • More expensive than other treatment options in primary care, although significantly less costly in secondary care